Advertisement

Advertisement

2016 ASH Annual Meeting

Advertisement

Advertisement



Sep
17
Today In Oncology
Patterns of Disease Progression in Patients With Unresectable Stage III NSCLC
Cancer Drugs Account for Over a Quarter of All New Drug Approvals in the US
Cost of Treatment, Prior Authorization of Treatment Plans May Cause Barriers to Care
Socioeconomic Deprivation and Outcomes in Cancer Clinical Trials
End-of-Life Care in Western Washington State vs Alberta, Canada
View More 
Advertisement
Most Read Stories
WCLC 2019: Two Studies Show Tumor Mutational Burden Not Associated With Pembrolizumab Efficacy in NSCLC
How I Work up the Patient with Thrombocytosis
WCLC 2019: KEYNOTE-024 Survival Update Shows Benefit With Pembrolizumab vs Chemotherapy in Advanced NSCLC
How Patient Advocacy Is Integral to High-Quality Oncology Care
Liquid Biopsy to Determine Patient Response to Immune Checkpoint Blockade
View More 
Most Viewed Videos
Ryan Huey, MD, on the Financial Toxicity of Early-Phase Clinical Trials
Margaret A. Tempero, MD, on Pancreatic Cancer: NCCN Guidelines Updates
Mallika Sharma, MPH, on Eliminating Prior Authorizations, Anxiety, Delay in Care, Higher Costs
Matthew B. Schabath, PhD, on Addressing Cultural Barriers to Equality in Oncology Among Sexual Gender Minorities
Brian I. Rini, MD, on Renal Cell Carcinoma: Results From the TIVO-3 Trial on Tivozanib vs Sorafenib
View More 
© 2019 HSP News Service, L.L.C.